Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease

A compound of formula (IV):

• or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:
• R1 is hydrogen, deuterium, —C1-6alkyl, deuterated —C1-6alkyl, heterocyclyl, heteroaryl, or aryl;
• wherein said —C1-6alkyl, deuterated —C1-6alkyl, heterocyclyl, heteroaryl, or aryl are each independently optionally substituted with at least one substituent R11a;
• each R11a is independently hydrogen, halogen, oxo, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, —OR1a, —COR1a, —CO2R1a, —CONR1aR1b, —SO2R1a, —NR1aR1b, —NR1aCOR1b, —NR1aCONR1bR1c or —NR1aCO2R1b;
• wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with at least one substituent R1d;
• R1a, R1b, and R1c are each independently hydrogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl;
• wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with at least one substituent R1d;
• each R1d is independently hydrogen, halogen, oxo, —CN, —NO2, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C1-6haloalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, —OC1-6alkyl, —COC1-6alkyl, or —CO2C1-6alkyl.
• R3 is hydrogen, halogen, —C1-6alkyl, —OC1-6alkyl, —CN, or —NO2;
• wherein said —C1-6alkyl or —OC1-6alkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, —C1-6alkyl, —CN, and —NO2;
• R4A and R4B, which may be the same or different, are each independently hydrogen, deuterium, halogen, —C1-6alkyl, or deuterated —C1-6alkyl;
• wherein said —C1-6alkyl or deuterated —C1-6alkyl is each independently optionally substituted with at least one substituent selected from halogen, —C1-6alkyl, —C1-6haloalkyl, —CN, —NO2, —OC1-6alkyl, —COC1-6alkyl, and —CO2C1-6alkyl;
• R4C is hydrogen, halogen, —C1-6alkyl or deuterated —C1-6alkyl;
• wherein said —C1-6alkyl or deuterated —C1-6alkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, —C1-6alkyl, —C1-6haloalkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, —OC1-6alkyl, —COC1-6alkyl, and —CO2C1-6alkyl;
• R5 is hydrogen, halogen, —C1-6alkyl, —OC1-6alkyl, —CN, or —NO2;
• wherein said —C1-6alkyl or —OC1-6alkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, —C1-6alkyl, —CN, and —NO2;
• R6 is hydrogen, halogen, —C1-6alkyl, —OC1-6alkyl, —CN, or —NO2;
• wherein said —C1-6alkyl or —OC1-6alkyl is each independently optionally substituted with at least one substituent selected from hydrogen, deuterium, halogen, —C1-6alkyl, —CN, and —NO2;
• R7 is hydrogen, halogen, —C1-6alkyl, —OC1-6alkyl, —CN, or —NO2;
• wherein said —C1-6alkyl or —OC1-6alkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, —C1-6alkyl, —CN, and —NO2;
• -L2A- is a covalent bond, *—N(R21a)C(O)—**, **—N(R21a)C(O)—*, *—(CR22aR23a)m—C(R22a)═C(R23a)—(CR22aR23a)n—**, or
• * refers to the position attached to the isoquinolin-1(2H)-one;
• ** refers to the position attached to R2A;
• m and n are each independently 0, 1, 2, or 3;
• R21a is hydrogen or —C1-6alkyl;
• wherein said —C1-6alkyl is optionally substituted with at least one substituent R211b;
• each R211b is independently hydrogen or halogen;
• R22a and R23a are each independently hydrogen, halogen, or —C1-6alkyl;
• wherein said —C1-6alkyl is each independently optionally substituted with at least one substituent R223a;
• each R223a is independently hydrogen or halogen;
• R2A is —C1-6alkyl, 3- to 15-membered cycloalkyl, unsaturated 3- to 15-membered heterocyclyl comprising at least one carbon-carbon double bond, 5- to 12-membered aryl, or 5- to 15-membered heteroaryl;
• wherein each of said —C1-6alkyl, 3- to 15-membered cycloalkyl, unsaturated 3- to 15-membered heterocyclyl comprising at least one carbon-carbon double bond, 5- to 12-membered aryl, or 5- to 15-membered heteroaryl is optionally substituted with at least one RY1;
• each RY1 is independently hydrogen, halogen, oxo, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, —O-heterocyclyl, —CO-heterocyclyl, aryl, heteroaryl, —P(O)(C1-6alkyl)2, —OH, —CN, —OC1-6alkyl, —SC1-6alkyl, or —NO2, wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, —OC1-6alkyl, or —SC1-6alkyl are each independently optionally substituted with at least one substituent RY1a;
• and
• each RY1a is independently hydrogen, halogen, —C1-6alkyl, —NHC1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, —OH, —CN, —CONH2, —COCH3, —OC1-6alkyl, or —NO2.